Figure 5.

ATRX knock-down increases the aggressiveness of sarcoma cells. (A) ATRX knock-down by shRNA validation in western blot in K7M2, MG63, and IB106 cell lines. (B) Proliferation analysis by MTT after four days, comparing ATRX^CT and ATRX^KD cells in K7M2, MG63, and IB106 cell lines (mean ± s.d.; n = 3 independent experiments). (C) Soft agar assay analysis comparing ATRX^CT and ATRX^KD cells in K7M2, MG63, and IB106 cell lines (mean ± s.d.; n = four independent experiments). Images were taken after four weeks and crystal violet staining. (D) Tumor growth rate analysis of IB106 ATRX^CT or IB106 ATRX^KD cells sub-cutaneous xenografts on NSG mice (n = 10 in each group). The growth rate was calculated by segmental linear regression with GraphPad. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, p-value was calculated with 2-way ANOVA for (A) and unpaired t-test for (B–D).